Human inducible pluripotent stem cells: Realization of initial promise in drug discovery

Robin J Kleiman; Sandra J Engle

doi:10.1016/j.stem.2021.08.002

Human inducible pluripotent stem cells: Realization of initial promise in drug discovery

Cell Stem Cell. 2021 Sep 2;28(9):1507-1515. doi: 10.1016/j.stem.2021.08.002.

Authors

Robin J Kleiman¹, Sandra J Engle²

Affiliations

¹ Research and Development, Biogen, 225 Binney Street, Cambridge, MA 02142, USA. Electronic address: robin.kleiman@biogen.com.
² Research and Development, Biogen, 225 Binney Street, Cambridge, MA 02142, USA. Electronic address: sandi.engle@biogen.com.

PMID: 34478628
DOI: 10.1016/j.stem.2021.08.002

Abstract

Over the course of the last decade, the biopharmaceutical industry has slowly adopted human inducible pluripotent stem cell (hiPSC) technology to enable the development of humanized model systems to test new therapeutic molecules and drug modalities. The adoption of hiPSC-based models by the industry has increased appreciably in the past 3-5 years. This increase has paralleled the explosion in availability of high-quality human genetic data to mine for new drug targets and the emergence of human-specific therapeutic modalities.

Keywords: disease models; drug discovery; hiPSC; high-throughput screening; microphysiological systems; pharmacology; toxicology.

Publication types

Review

MeSH terms

Drug Discovery
Humans
Induced Pluripotent Stem Cells*
Models, Biological
Myocytes, Cardiac
Pluripotent Stem Cells*